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445Abstracts
OBJECTIVES: Health care costs incurred for particular
diseases express priorities and can show future directions
for targeting resources. Because these costs are difﬁcult 
to obtain, there are hardly any reliable estimates in
Germany. The analysis intends to show a new approach
to estimate expenditures for CHD borne by the statutory
health insurance in Germany. METHODS: We identiﬁed
roughly 4 million individuals by pre-selected indicator
medications for ﬁve different diseases namely asthma,
diabetes, heart failure, hypertension and CHD. Individu-
als were selected for inclusion if these indicator medica-
tions were administered to them at least once in the year
1999. Indicator medications for CHD were nitrates and
molsidomine. Expenditures for individuals with CHD
were compared to average age- and gender-speciﬁc expen-
ditures for individuals without CHD. To ﬁnd the portion
of the difference, which could be attributed to CHD on
the one hand and to other diseases on the other hand, 
the strong correlation of disease occurrence was
accounted for in a stepwise procedure. RESULTS:
Approximately half of the cost difference between CHD-
cases and non-CHD cases could be explained by the pres-
ence of CHD and the other half by concurrent diseases.
The total costs attributed to CHD sum up to some $5
billion. As a whole the statutory health insurance spends
roughly $130 billion per year. CONCLUSIONS: Com-
pared with the total health care budget, CHD accounts
for roughly 4% of health care expenditures if inter-disease
correlations are considered. This amount seems low given
the fact that CHD accounts for more than 20% of deaths
in Germany. The strong interactivity of disease concern-
ing health care costs might imply that they should not be
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OBJECTIVES: To compare hospital, procedural, and
ambulatory hypertension costs across eight countries
(Australia, Canada, France, Germany, Italy, Spain, UK
and the US) and document factors to consider when
making multinational comparisons. METHODS: Data
was obtained from health economics resources in each
country and an international literature search. Public and
private sources such as UK’s Royal London NHS Trust,
Personal Social Services Research Unit, and NHS Execu-
tive were used. Data tables captured four hypertension-
related events: Acute Myocardial Infarct (AMI),
Congestive Heart Failure (CHF), Stroke, and Renal
Failure (RF). All costs were converted into US Dollars for
the year 2000. RESULTS: There are considerable inter-
national variations in the hospitalization, procedural and
ambulatory hypertension treatment costs. These differ-
ences can be explained partially by the source of payment,
measurement of overhead, physician and hotel fees, and
prevailing practice patterns, as well as whether account-
ing costs or actual expenditures were used. US costs
appear to be higher for AMI, stroke and renal failure hos-
pitalizations, while CHF hospitalization costs are similar
across countries. The reported AMI hospitalization cost,
as a percentage of the US cost, ranges from 7.1% (UK)
to 43.5% (Spain). The UK and Australia appear to have
the lowest hospital-related and ambulatory costs across
all four events. Ambulatory costs for 1 year after an AMI,
CHF, transplantation or stroke hospitalization are highest
in the US. Typically the procedural and line item costs
were higher in the US than in other countries. Reported
CABG procedure costs ranged from 2.6% (France) to
51.8% (Italy) of US costs. CONCLUSIONS: We found
wide variation in captured and reported costs for hyper-
tension-related hospitalizations, procedures, and ambula-
tory care. Health services researchers should be cautious
when constructing or interpreting international compar-
isons, particularly in differentiating between actual cost
differences, differences in deﬁnition of services measured,
and national practice patterns.
INFECTIOUS DISEASE STUDIES I
IN1
A BAYESIAN APPROACH TO NET HEALTH
BENEFITS:AN ILLUSTRATION AND
APPLICATION TO MODELING HIV 
PREVENTION
Johnson-Masotti A1, Laud P2, Hoffmann R2, Hayat M2,
Pinkerton S2
1McMaster University, Hamilton, ON, Canada; 2Medical
College of Wisconsin, Milwaukee, WI, USA
OBJECTIVES: The present study presents a Bayesian
cost-effectiveness analysis of HIV prevention in the
instance when costs and effects cannot be measured
directly. METHODS: A Bayesian approach to cost-
effectiveness analysis was illustrated using empirical data
from an HIV prevention randomized trial. We computed
incremental net health beneﬁt (INHB), and the analysis
was conducted from the societal perspective. Intervention
costs were estimated retrospectively. Clients were ran-
domized into an intervention (advocacy training) (N = 15)
or comparison condition (N = 15). Risk behavior data
were collected at baseline and three months after the end
of each intervention. In the Bayesian framework, we con-
sidered what could occur in a conceptual future study that
is an identical replicate to the one actually conducted.
Using posterior distribution of the behavior parameters,
we sampled 5000 replicates. With the use of a Bernoulli
model of HIV transmission, changes in the participants’
HIV risk were combined with HIV transmission parame-
ters (drawn from their respective prior distributions) and
